ReNeuron’s human retinal progenitor cell therapy candidate for retinitis pigmentosa has shown a mean improvement in visual acuity in a phase 1/2a clinical trial, according to a press release.
In the phase 2a segment of the study, which used a cryopreserved human retinal progenitor cell (hRPC) formulation, visual acuity improvement was 8.3 ETDRS letters in the treated eye compared with 1.6 letters in the untreated eye. After 6 months, the treatment eye saw a mean visual acuity improvement of 18.5 letters compared with 7.8 letters in the untreated eye, whereas (Read more...)
Uncategorized